Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):586–587. doi: 10.1128/aac.40.3.586

Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.

H W Murray 1, J Hariprashad 1
PMCID: PMC163162  PMID: 8851575

Abstract

BALB/c mice with established visceral infection caused by the intracellular protozoan Leishmania donovani were treated with oral atovaquone for 7 days. Treatment with 100 mg/kg of body weight per day was optimal and halted parasite replication in the liver. In mice treated with atovaquone, the effect of a suboptimal dose of pentavalent antimony was converted from partially leishmanistatic to leishmanicidal. These results demonstrate the in vivo antileishmanial effect of atovaquone and suggest a potential role for this oral agent in visceral leishmaniasis as an adjunct to conventional antimony treatment.

Full Text

The Full Text of this article is available as a PDF (157.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brun-Pascaud M., Chau F., Simonpoli A. M., Girard P. M., Derouin F., Pocidalo J. J. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis. J Infect Dis. 1994 Sep;170(3):653–658. doi: 10.1093/infdis/170.3.653. [DOI] [PubMed] [Google Scholar]
  2. Chunge C. N., Owate J., Pamba H. O., Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg. 1990 Mar-Apr;84(2):221–225. doi: 10.1016/0035-9203(90)90263-e. [DOI] [PubMed] [Google Scholar]
  3. Croft S. L., Hogg J., Gutteridge W. E., Hudson A. T., Randall A. W. The activity of hydroxynaphthoquinones against Leishmania donovani. J Antimicrob Chemother. 1992 Dec;30(6):827–832. doi: 10.1093/jac/30.6.827. [DOI] [PubMed] [Google Scholar]
  4. Herwaldt B. L., Berman J. D. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992 Mar;46(3):296–306. doi: 10.4269/ajtmh.1992.46.296. [DOI] [PubMed] [Google Scholar]
  5. Hughes W. T. A new drug (566C80) for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1992 Jun 1;116(11):953–954. doi: 10.7326/0003-4819-116-11-953. [DOI] [PubMed] [Google Scholar]
  6. Hughes W. T., Gray V. L., Gutteridge W. E., Latter V. S., Pudney M. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1990 Feb;34(2):225–228. doi: 10.1128/aac.34.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mishra M., Biswas U. K., Jha A. M., Khan A. B. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet. 1994 Dec 10;344(8937):1599–1600. doi: 10.1016/s0140-6736(94)90406-5. [DOI] [PubMed] [Google Scholar]
  8. Murray H. W., Berman J. D., Wright S. D. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis. 1988 May;157(5):973–978. doi: 10.1093/infdis/157.5.973. [DOI] [PubMed] [Google Scholar]
  9. Murray H. W., Hariprashad J., Fichtl R. E. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother. 1993 Jul;37(7):1504–1505. doi: 10.1128/aac.37.7.1504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Olliaro P. L., Bryceson A. D. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today. 1993 Sep;9(9):323–328. doi: 10.1016/0169-4758(93)90231-4. [DOI] [PubMed] [Google Scholar]
  11. Romand S., Pudney M., Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother. 1993 Nov;37(11):2371–2378. doi: 10.1128/aac.37.11.2371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Seaman J., Pryce D., Sondorp H. E., Moody A., Bryceson A. D., Davidson R. N. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis. 1993 Sep;168(3):715–720. doi: 10.1093/infdis/168.3.715. [DOI] [PubMed] [Google Scholar]
  13. Sherwood J. A., Gachihi G. S., Muigai R. K., Skillman D. R., Mugo M., Rashid J. R., Wasunna K. M., Were J. B., Kasili S. K., Mbugua J. M. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis. 1994 Dec;19(6):1034–1039. doi: 10.1093/clinids/19.6.1034. [DOI] [PubMed] [Google Scholar]
  14. Sundar S., Rosenkaimer F., Lesser M. L., Murray H. W. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis. 1995 Apr;171(4):992–996. doi: 10.1093/infdis/171.4.992. [DOI] [PubMed] [Google Scholar]
  15. Sundar S., Rosenkaimer F., Murray H. W. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis. 1994 Sep;170(3):659–662. doi: 10.1093/infdis/170.3.659. [DOI] [PubMed] [Google Scholar]
  16. Thakur C. P., Kumar M., Kumar P., Mishra B. N., Pandey A. K. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) 1988 Jun 4;296(6636):1557–1561. doi: 10.1136/bmj.296.6636.1557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Thakur C. P., Kumar M., Pandey A. K. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg. 1991 Oct;45(4):435–441. doi: 10.4269/ajtmh.1991.45.435. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES